Janssen's 'queue jumping' plan

Posted December 6 2021 PM

Australians are waiting longer for the reimbursement of new medicines than many of their overseas counterparts, with the average new medicine taking more than a year to get reimbursed, but the Covid pandemic demonstrated it doesn't have to be this way.

A new report by Johnson & Johnson, Getting Australia to the Front of the Queue, suggests changes to the Health Technology Assessment process and the PBAC remit, citing the speed with which COVID-19 vaccines were brought to market as an alternative to the current time frames.

To see the whole article, please login